Vardenafil


Description

Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by th...

Read more

Pharmacology

Indication

Used for the treatment of erectile dysfunction

Pharmacodynamic

Vardenafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertensio... Read more

Mechanism of action

Vardenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degra... Read more

Absorption

Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.

Protein binding

95%

Volume of distribution

208 L

Clearance

56 L/h

Half life

4-5 hours

Route of elimination

After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approxi... Read more

Toxicity

Symptoms of overdose include vision changes and back and muscle pain.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Headache US
  • Kind: experimental
    • Percent: 15%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Flushing US
  • Kind: experimental
    • Percent: 11%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Rhinitis US
  • Kind: experimental
    • Percent: 9%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Dyspepsia US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Sinusitis US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Flu syndrome US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Gastrointestinal and abdominal pain US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Hypotension US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Ventricular Tachyarrhythmias US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Myocardial Infarction US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Gastritis US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Gastroesophageal Reflux Disease US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Dry Mouth US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Somnolence US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Paresthesia and dysesthesia US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Myalgia US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Increased muscle tone and cramping US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Increase in creatine phosphokinase (CPK) US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Increase in transaminases US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Dyspnea US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Seizure US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Amnesia US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Syncope US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Sleep Disorder US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Increased creatine kinase US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Feeling unwell US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Allergic Reactions US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 2.0%
  • Kind: placebo
    • Percent: 1.7%
  • Clinical Trial
    Angioedema US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Allergic edema US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Palpitation US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Angina Pectoris US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Tachycardia US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Tinnitus US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Chest Pain US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Vertigo US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Sinus Congestion US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Erythema US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Visual Disturbance US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Ocular hyperemia US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Visual color distortions US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Eye pain and eye discomfort US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Photophobia US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial
    Increase in intraocular pressure US
  • Kind: experimental
    • Percent: <2%
  • Clinical Trial

    Contraindications

    • Regions: US
    • With Categories Coadmin:
        • Name: Soluble Guanylate Cyclase Stimulator
        • Drugbank Id: DBCAT003503
    • Regions: US
    • With Drugs Coadmin:
        • Name: Nitrate
        • Drugbank Id: DB14049
    • Regions: US
    • With Categories Coadmin:
        • Name: Nitric Oxide Donors
        • Drugbank Id: DBCAT000756
        • Mesh Id: D020030

    Food Interactions

      Information currently not available.

    Interactions

    Type in a drug name to check for interaction with Vardenafil

    The metabolism of Vardenafil can be decreased when combined with (R)-warfarin.
    The metabolism of Vardenafil can be decreased when combined with (S)-Warfarin.
    The metabolism of Vardenafil can be decreased when combined with 3,5-diiodothyropropionic acid.
    The metabolism of 4-hydroxycoumarin can be decreased when combined with Vardenafil.
    The metabolism of Vardenafil can be decreased when combined with 5-androstenedione.
    The metabolism of Vardenafil can be decreased when combined with 6-Deoxyerythronolide B.
    The metabolism of Vardenafil can be decreased when combined with 6-O-benzylguanine.
    The metabolism of Vardenafil can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
    The metabolism of Vardenafil can be decreased when combined with 9-aminocamptothecin.
    The metabolism of Vardenafil can be increased when combined with Abatacept.
    The metabolism of Vardenafil can be decreased when combined with Abemaciclib.
    The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Abexinostat.
    The metabolism of Vardenafil can be decreased when combined with Abiraterone.
    The metabolism of Vardenafil can be decreased when combined with Acalabrutinib.
    Vardenafil may increase the antihypertensive activities of Acebutolol.
    The metabolism of Acenocoumarol can be decreased when combined with Vardenafil.
    The risk or severity of hypotension, dyspepsia, and headache can be increased when Vardenafil is combined with Acepromazine.
    The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Aceprometazine.
    The metabolism of Vardenafil can be decreased when combined with Acetaminophen.
    The metabolism of Vardenafil can be decreased when combined with Acetazolamide.

    References

      Information currently not available.

    Recent Questions